BENTON, Ark.–(BUSINESS WIRE)–In observance of National Patient Safety Awareness Week (March 10-16, 2024), HD Nursing, the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention, is pleased to highlight its recent positive benchmarks, underscoring the top-down commitment to advancing patient safety.
“Patient safety is at the heart of everything we do at HD Nursing, and we’re proud to contribute to a culture of safety that enhances patient outcomes and sets new standards in healthcare,” says Dr. Amy Hester, PhD, RN, BC, FAAN, chairwoman and CEO, HD Nursing. “These positive benchmarks underscore the effectiveness of our Falls Prevention Program and the unwavering commitment of healthcare providers to prioritize patient safety. As we mark National Patient Safety Awareness Week, these achievements inspire us to continue pioneering innovative solutions that make a meaningful impact on healthcare outcomes.”
About HD Nursing
HD Nursing is the dominant patient safety solution that combines predictive analytics with individualized fall and fall injury prevention patient care. Offering the only fall risk assessment tool validated in the electronic medical record, and a program that is a comprehensive, evidence-based approach to reduce patient falls and injuries, the HD Nursing falls solution is employed by leading health systems and academic medical centers across the U.S. Leveraging EHR functionality and communication technologies, new HD Programs in Community Fall Prevention and Pressure Injury Prevention, showcase HD Nursing’s dedication to improving multiple patient safety initiatives across the continuum of care. Since the company’s inception in 2012, HD Nursing has been fully committed to the promotion of diversity, equity and inclusion, which are essential in its constant pursuit of excellence as a national leader in patient safety.
Contacts
Brittany Tedesco
btedesco@cpronline.com
201.641.1911 x 14
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…